DSNKY Daiichi Sankyo Company Ltd (PK)

   By Elena Vardon 
 

AstraZeneca said Monday that the phase II trial for its cancer drug Enhertu showed clinically meaningful and durable responses across patients with HER2-expressing advanced solid tumours who had been previously treated.

The Anglo-Swedish pharma giant said interim results from its DESTINY-PanTumor02 Phase 2 trial showed an objective response rate of 37.1% in the trial's overall population and also demonstrated positive antitumor activity in patients previously treated for HER2-positive metastatic colorectal cancer.

Enhertu, or trastuzumab deruxtecan, is being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.

Write to Elena Vardon at elena.vardon@wsj.com

(END) Dow Jones Newswires

June 05, 2023 08:38 ET (12:38 GMT)

Daiichi Sankyo (PK) (USOTC:DSNKY)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Daiichi Sankyo (PK) (USOTC:DSNKY)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024